Novel Pharmacological Treatments Revolutionize Obesity Management with Incretin-Based Therapies

Obesity is recognized as an adiposity-based chronic disease, with Body Mass Index (BMI) serving as a primary therapeutic target to prevent associated complications. Current treatment guidelines recommend a stepwise approach, beginning with multifactorial basal therapy including nutrition counseling, exercise, and behavior modification. However, there has historically been a significant gap in highly effective pharmacological interventions that could bridge the efficacy gap between lifestyle changes and bariatric surgery.

The review highlights an impressive improvement in the effectiveness of obesity medications, primarily driven by incretin-based therapies that activate GLP-1 and GIP receptors to increase satiety. Trial data revealed substantial average weight losses: liraglutide led to an average weight loss of 7.5 kg after 160 weeks of treatment. Semaglutide demonstrated even greater efficacy, with an average weight loss of up to 17.4 kg after 68 weeks. The most significant finding was with tirzepatide, which achieved an average weight loss of up to 22.5 kg after 72 weeks, closely approaching the outcomes typically seen with bariatric interventions. Furthermore, semaglutide also showed positive results in cardiovascular outcome trials, indicating benefits beyond just weight reduction.